-
公开(公告)号：US11737357B2
公开(公告)日：2023-08-22
申请号：US15770633
申请日：2016-10-27
申请人： LG Chem, Ltd.
发明人： Miyeon Han , Dong Hoon Lee , Jungoh Huh , Boonjae Jang , Minyoung Kang , Dong Uk Heo , Min Woo Jung
IPC分类号： H10K85/60 , C07D235/06 , C07D251/12 , C07D263/52 , C07D277/60 , C09K11/06 , H10K50/12 , H10K50/15 , H10K50/16 , H10K50/18 , H10K50/81 , H10K50/82 , H10K50/17 , H10K71/16 , C07D403/10 , C07D251/24 , C07D405/10 , C07D409/10 , C07D413/10 , C07D471/04
CPC分类号： H10K85/654 , C07D235/06 , C07D251/12 , C07D251/24 , C07D263/52 , C07D277/60 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D471/04 , C09K11/06 , H10K50/12 , H10K50/15 , H10K50/16 , H10K50/171 , H10K50/18 , H10K50/81 , H10K50/82 , H10K71/164 , H10K85/615 , H10K85/626 , H10K85/6572 , H10K85/6574 , H10K85/6576
摘要： The present application relates to a compound of Chemical Formula 1 and an organic light emitting device including the same.
-
公开(公告)号：US20230157161A1
公开(公告)日：2023-05-18
申请号：US17950312
申请日：2022-09-22
发明人： Xiangzhi LI , Ye CAI , Ting-Wei WEI , Zhi-Kuan CHEN
IPC分类号： H01L51/00 , C07D403/04 , C07D405/14 , C07D403/14 , C07D263/52 , C07D413/12
CPC分类号： H01L51/0067 , C07D403/04 , C07D405/14 , H01L51/0072 , H01L51/0073 , C07D403/14 , C07D263/52 , H01L51/0061 , C07D413/12 , H01L51/0071 , H01L51/5012
摘要： The present invention provides an organic material composition and applications thereof. By the combination of the compounds comprised in the organic material composition, the organic material composition makes the element have a lower driving voltage, a higher current efficiency and a longer service life.
-
公开(公告)号：US20210230176A1
公开(公告)日：2021-07-29
申请号：US17143326
申请日：2021-01-07
发明人： Yao-Ling Qiu , Xuri Gao , Wei Li , Hui Cao , Meizhong Jin , Jorden Kass , Xiaowen Peng , Yat Sun Or
IPC分类号： C07D493/08 , C07C317/44 , C07C323/62 , A61K31/167 , A61K31/18 , A61K31/196 , A61K31/215 , A61K31/223 , A61K31/277 , A61K31/325 , A61K31/335 , A61K31/336 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/365 , A61K31/39 , A61K31/401 , A61K31/41 , A61K31/415 , A61K31/416 , A61K31/4164 , A61K31/421 , A61K31/426 , A61K31/439 , A61K31/44 , A61K31/4402 , A61K31/4409 , A61K31/4425 , A61K31/445 , A61K31/4545 , A61K31/5377 , A61K31/655 , C07B59/00 , C07C235/56 , C07C311/53 , C07C317/32 , C07C323/42 , C07D207/16 , C07D211/54 , C07D213/52 , C07D213/81 , C07D213/89 , C07D231/12 , C07D233/64 , C07D257/04 , C07D261/02 , C07D261/08 , C07D261/20 , C07D263/52 , C07D277/26 , C07D295/088 , C07D303/26 , C07D303/34 , C07D307/32 , C07D307/33 , C07D309/08 , C07D313/04 , C07D317/72 , C07D327/10 , C07D401/04 , C07D451/04 , C07D493/04
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20180339993A1
公开(公告)日：2018-11-29
申请号：US16050514
申请日：2018-07-31
申请人： RaQualia Pharma Inc.
发明人： Yuji SHISHIDO , Masashi OHMI , Kazuo ANDO
IPC分类号： C07D491/056 , A61K31/538 , C07D235/06 , A61K31/423 , A61K31/4355 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/498 , A61K31/4985 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/506 , A61K31/519 , C07D413/10 , C07D235/02 , A61K31/517 , A61K31/435 , A61K31/422 , A61K31/4178 , C07D491/048 , C07D263/52 , C07D487/04 , C07D471/04 , C07D417/14 , C07D417/10 , C07D417/06 , C07D413/06 , C07D409/14 , C07D409/10 , C07D403/14 , C07D403/10 , C07D403/06 , C07D401/12 , A61K31/437 , A61K31/427 , C07D413/14 , C07D405/14 , C07D401/14 , C07D403/12 , A61K31/4184
摘要： The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor,
-
公开(公告)号：US20180230111A1
公开(公告)日：2018-08-16
申请号：US15887956
申请日：2018-02-02
发明人： Andrew G. Myers , Mark G. Charest , Christian D. Lerner , Jason D. Brubaker , Dionicio R. Siegel
IPC分类号： C07D261/20 , C07C231/10 , C07D277/66 , C07D307/77 , C07C237/26 , C07D209/56 , C07D209/58 , C07D213/56 , C07D221/18 , C07D235/02 , C07D237/26 , C07D239/70 , C07D241/38 , C07D263/52 , C07D277/30 , C07D277/56 , C07D277/64
摘要： The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.
-
公开(公告)号：US09890177B2
公开(公告)日：2018-02-13
申请号：US14920156
申请日：2015-10-22
IPC分类号： C07D498/10 , A01N43/76 , A01N43/90 , C07C201/08 , C07C201/12 , C07C205/02 , C07C205/06 , C07C205/18 , C07C215/08 , C07C215/42 , C07C239/10 , C07D263/04 , C07D263/52 , C07D498/04 , C08G18/32 , C07C205/04 , C07C205/05 , C07C205/15 , C07C205/16 , C07C215/20 , C07C215/28
CPC分类号： C07D498/10 , A01N43/76 , A01N43/90 , C07C201/08 , C07C201/12 , C07C205/02 , C07C205/04 , C07C205/05 , C07C205/06 , C07C205/15 , C07C205/16 , C07C205/18 , C07C215/08 , C07C215/20 , C07C215/28 , C07C215/42 , C07C239/10 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/10 , C07D263/04 , C07D263/52 , C07D498/04 , C08G18/3271 , Y02P20/582
摘要： Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compounds, as well as novel nitrated compounds and derivatives, and methods of using the derivatives in various applications.
-
公开(公告)号：US09884830B2
公开(公告)日：2018-02-06
申请号：US15161165
申请日：2016-05-20
发明人： Andrew G. Myers , Mark G. Charest , Christian D. Lerner , Jason D. Brubaker , Dionicio R. Siegel
IPC分类号： C07D413/00 , C07C237/26 , C07D261/20 , C07D209/56 , C07D209/58 , C07D213/56 , C07D221/18 , C07D235/02 , C07D237/26 , C07D239/70 , C07D241/38 , C07D263/52 , C07D277/30 , C07D277/56 , C07D277/64 , C07D277/66 , C07D307/77 , C07C231/10
CPC分类号： C07D261/20 , C07C231/10 , C07C237/26 , C07D209/56 , C07D209/58 , C07D213/56 , C07D221/18 , C07D235/02 , C07D237/26 , C07D239/70 , C07D241/38 , C07D263/52 , C07D277/30 , C07D277/56 , C07D277/64 , C07D277/66 , C07D307/77
摘要： The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.
-
公开(公告)号：US20160235716A1
公开(公告)日：2016-08-18
申请号：US14857419
申请日：2015-09-17
申请人： ABBVIE INC.
发明人： Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC分类号： A61K31/4184 , C07D403/06 , C07D405/06 , A61K31/423 , C07D401/06 , A61K31/4439 , C07D263/52 , C07D235/02 , C07D409/06
CPC分类号： A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
摘要： Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1- - - -Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
摘要翻译： 具有式（IX）结构的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中R1，R2a，R2b，R3a，R3b，R4a，R4b，Q1- - -Q2，R6，R7，A，B ，W，x和y如本文所定义并提供。 还提供了包含这些化合物的药物组合物和通过施用这些化合物治疗各种HAT相关病症或疾病（包括癌症）的方法。
-
公开(公告)号：US20160157485A1
公开(公告)日：2016-06-09
申请号：US14903169
申请日：2014-07-01
发明人： Anthony Cornelius O-Sullivan , Regis Jean Georges Mondiere , Olivier Loiseleur , Tomas Smejkal , Torsten Luksch , Andre Jeanguenat , Raphael Dumeunier , Edouard Godineau , Thomas Pittema
IPC分类号： A01N37/18 , A01N43/20 , C07C251/44 , C07C233/66 , C07D213/82 , A01N43/40 , C07C211/37 , C07C233/32 , C07C233/23 , C07C233/14 , C07C233/90 , C07D263/52 , C07C291/10 , C07C265/10 , C07C317/32 , C07D305/08
CPC分类号： A01N37/18 , A01N37/34 , A01N37/40 , A01N43/20 , A01N43/40 , C07B2200/07 , C07C211/37 , C07C233/14 , C07C233/23 , C07C233/32 , C07C233/66 , C07C233/81 , C07C233/90 , C07C235/54 , C07C235/62 , C07C251/44 , C07C255/57 , C07C265/10 , C07C291/10 , C07C317/32 , C07C323/62 , C07C2601/04 , C07D213/81 , C07D213/82 , C07D231/14 , C07D239/28 , C07D263/52 , C07D305/08
摘要： Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.
摘要翻译： 其中取代基如权利要求1中所定义的式（I）化合物适合用作杀线虫剂。
-
10.发明授权公开(公告)号：US09249084B2
公开(公告)日：2016-02-02
申请号：US13982733
申请日：2012-01-31
申请人： Qiang Zhang , Rongxia Zhang , Guanghui Tian , Jianfeng Li , Fuqiang Zhu , Xiangrui Jiang , Jingshan Shen
发明人： Qiang Zhang , Rongxia Zhang , Guanghui Tian , Jianfeng Li , Fuqiang Zhu , Xiangrui Jiang , Jingshan Shen
IPC分类号： C07C213/02 , C07C59/64 , C07C235/34 , C07C309/75 , C07C309/66 , C07C43/225 , C07D263/26 , C07C17/16 , C07C215/54 , C07C217/62 , C07C309/73 , C07D263/52 , C07C43/23 , C07C59/68 , C07C41/26
CPC分类号： C07C235/34 , C07C17/16 , C07C41/26 , C07C43/225 , C07C43/23 , C07C59/64 , C07C59/68 , C07C213/02 , C07C215/54 , C07C217/62 , C07C309/66 , C07C309/73 , C07C309/75 , C07D263/26 , C07D263/52 , Y02P20/582 , C07C22/04
摘要： The present invention relates to a (2R,3R)-3-(3-substituted phenyl)-2-methyl n-pentanamide compounds as shown in the formula I and the preparation method thereof, wherein, the substituents are as defined in the specification, the present invention further relates to a use of the above compounds for the preparation of tapentadol II or its pharmaceutically acceptable salt, and the intermediates involved in the preparation process.
摘要翻译： 本发明涉及式I所示的（2R，3R）-3-（3-取代苯基）-2-甲基正戊酰胺化合物及其制备方法，其中取代基如本说明书中所定义 ，本发明还涉及上述化合物在制备他喷他多II或其药学上可接受的盐中的用途，以及参与制备方法的中间体。
-
-
-
-
-
-
-
-
-
搜索结果
462 条记录 (耗时 0.061 秒)
